Claims
- 1. (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt.
- 2. (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt, monohydrate.
- 3. A pharmaceutical composition comprising
(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt; and. (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 4. A pharmaceutical composition comprising
(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt, monohydrate; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 5. A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt; or (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate.
- 6. A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition comprising
(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 7. A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition comprising
(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 8. The method of claim 5, 6 or 7 wherein said β3-adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, irritable bowel syndrome, inflammatory bowel disease, esophagitis, duodenitis, Crohn's Disease, proctitis, asthma, intestinal motility disorder, ulcer, gastritis, hypercholesterolemia, cardiovascular disease, urinary incontinence, depression, prostate disease, dyslipidemia, and airway inflammatory disorder.
- 9. The method of claim 8 wherein said β3-adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, urinary incontinence, and irritable bowel syndrome.
- 10. A method of increasing lean meat content of an edible animal which method comprises administering to said edible animal a lean meat increasing amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt; or (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt, monohydrate.
- 11. A method of increasing lean meat content of an edible animal which method comprises administering to said edible animal a lean meat increasing amount of a pharmaceutical composition comprising
(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 12. A method of increasing lean meat content of an edible animal which method comprises administering to said edible animal a lean meat increasing amount of a pharmaceutical composition comprising
(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/360,248 filed Feb. 27, 2002 and incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60360252 |
Feb 2002 |
US |